MMJ International Holdings, a pharmaceutical enterprise focused on the improvement of cannabis-primarily based therapeutic goods, will quickly commence testing its oral cannabidiol ( CBD) and tetrahydrocannabinol (THC) goods in U.S. clinical trials for Huntington’s illness and a number of sclerosis.

The U.S. Drug Enforcement Administration (DEA) cleared MMJ to import the compounds from Canada, just after the enterprise produced the request 3 months ago.

The cannabis plant produces a assortment of compounds recognized as cannabinoids, which includes THC and CBD, two of the most abundant discovered in the plant. CBD, the non-psychoactive element of cannabis, is believed to have neuroprotective properties, although THC is the most important psychoactive constituent of cannabis.

These chemical substances bind to cannabinoid receptors in the brain, thereby altering the release of chemical messengers that are needed for nerve cells to communicate.

Even though cannabinoids have been studied for a assortment of neurologic issues, research indicate that these compounds may possibly be capable to ease Huntington’s illness motor symptoms. Furthermore, sturdy proof suggests that these cannabinoids can also be beneficial to treat spasticity and neuropathic discomfort in a number of sclerosis (MS).

MMJ-001 and MMJ-002 are two of MMJ’s lead therapeutic candidates, and are liquid formulations of hugely purified THC and CBD.

The enterprise is establishing MMJ-001 to treat spasticity (abnormal muscle tightness) in MS, and MMJ-002 to treat Huntington’s-related chorea — a neurological situation marked by involuntary spasms or writhing movements.

The U.S. Meals and Drug Administration (FDA) granted Orphan Drug Designation to MMJ-002 in January 2019 to advance the candidate’s improvement as a therapy for Huntington’s.

“We firmly think that our MMJ all-natural entire plant derived molecules with a distinctive mixture of pharmacological properties will be FDA authorized as a protected and helpful prescription drug that can be of fantastic advantage in treating individuals with MS and [Huntington’s] ailments,” Duane Boise, CEO of MMJ International Holdings, mentioned in a press release.

“We are pleased with the DEA’s cooperation and assistance to facilitate our enterprise mission to service the unmet requires of individuals suffering from these chronic ailments,” he added.

The DEA had asked MMJ to deliver the active pharmaceutical components of its proprietary THC and CBD formulations to be utilized in clinical trials. Despite the fact that facts of such research have been not talked about in the release, Tim Moynahan, enterprise chairman, mentioned: “Patients in the MMJ International holdings clinical trials will acquire gelatine capsules containing THC and CBD day-to-day.”

A specialty pharmaceutical options enterprise will support MMJ with specialized liquid encapsulation options, and make confident MMJ follows FDA protocol and DEA manufacturing suggestions.

At present, various academic institutions are in touch with MMJ to prepare research of cannabis as a therapy for Huntington’s illness and MS.

“MMJ clinical trials will deliver the needed information to prove that cannabis can treat critical tremors, a neurological disorder that causes involuntary shaking. In the end, there’s so significantly interest in THC and CBD as a therapy modality, so MMJ will be giving the clinical study information needed to prove patient dosing, security, and efficacy,” Moynahan stated.

When asked about probable dates for the commercialization of their goods, Boise mentioned in a Might interview with the Jamaica Observer: “The FDA desires us to be confident the actives are not altering and what the anticipated shelf life of the medicine will be. Pending any additional FDA test, we anticipate 18–24 months ahead of we can commercialize the drug. Throughout that time, we will be conducting our Phase two clinical trial.”

With more than 3 years of encounter in the health-related communications small business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical study.

Total Posts: 79

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. Immediately after leaving the lab to pursue a profession in Science Communication, she served as the Director of Science Communication at iMM.